|
|
|
|
|
by viraptor
1296 days ago
|
|
When testing and during early phases of deployment you'd track a sample of different cohorts more closely. Either explicitly by retesting a selected group, or analysing data from groups sampled anyway (many emergency doctors got a weekly test). So as Usual in studies - through data collection, statistics, and correcting for bias in cohorts. > afaik the mRNA vaccines were fast tracked, leaving room for possible errors There's already lots of information about the details of what the fast tracking meant. I would recommend reading some to understand it better than your summary. |
|
I just read this: https://www.reuters.com/article/factcheck-pfizer-vaccine-tra...
> The same presentation slide describes “Other benefits likely uncertain at approval and only clearer after the vaccine is used” to include the vaccine’s “long term protection,” “prevention of infection (asymptomatic cases),” and “prevention of virus transmission in the community - needs specific studies post-approval necessary to show.”
This implies they only checked it reduces symptoms in affected. Transmission prevention and long term immunity would be tested at later point.
So what was then the point of getting everyone vaccinated? Weren't vaccines supposed to contain its spread?
When I got vaccinated for various diseases, it gave long term immunity, not 4 doses over months to lessen the symptoms.